Press Releases

September 26, 2022

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Press Releases

September 26, 2022

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Press Releases

September 26, 2022

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Press Releases

September 26, 2022

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Press Releases

September 26, 2022

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Press Releases

September 26, 2022

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Press Releases

September 23, 2022

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Press Releases

September 23, 2022

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Press Releases

September 23, 2022

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Press Releases

September 23, 2022

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Press Releases

September 23, 2022

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Press Releases

September 23, 2022

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Press Releases

July 21, 2022

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Press Releases

July 21, 2022

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Press Releases

July 21, 2022

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Press Releases

July 21, 2022

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Press Releases

July 21, 2022

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Press Releases

July 21, 2022

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Press Releases

June 29, 2022

Acticor Biotech announces the issuance of a patent in Europe for glenzocimab, its innovative product for the treatment of cardiovascular emergencies

Press Releases

June 29, 2022

Acticor Biotech announces the issuance of a patent in Europe for glenzocimab, its innovative product for the treatment of cardiovascular emergencies

Press Releases

June 29, 2022

Acticor Biotech announces the issuance of a patent in Europe for glenzocimab, its innovative product for the treatment of cardiovascular emergencies

Press Releases

June 29, 2022

Acticor Biotech announces the issuance of a patent in Europe for glenzocimab, its innovative product for the treatment of cardiovascular emergencies

Press Releases

June 29, 2022

Acticor Biotech announces the issuance of a patent in Europe for glenzocimab, its innovative product for the treatment of cardiovascular emergencies

Press Releases

June 29, 2022

Acticor Biotech announces the issuance of a patent in Europe for glenzocimab, its innovative product for the treatment of cardiovascular emergencies

Press Releases

May 9, 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Press Releases

May 9, 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Press Releases

May 9, 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Press Releases

May 9, 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Press Releases

May 9, 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Press Releases

May 9, 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Press Releases

April 27, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Press Releases

April 27, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Press Releases

April 27, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Press Releases

April 27, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Press Releases

April 27, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Press Releases

April 27, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Press Releases

March 30, 2022

2021 full year financial results and update on clinical development

Press Releases

March 30, 2022

2021 full year financial results and update on clinical development

Press Releases

March 30, 2022

2021 full year financial results and update on clinical development

Press Releases

March 30, 2022

2021 full year financial results and update on clinical development

Press Releases

March 30, 2022

2021 full year financial results and update on clinical development

Press Releases

March 30, 2022

2021 full year financial results and update on clinical development

Press Releases

March 8, 2022

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Press Releases

March 8, 2022

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Press Releases

March 8, 2022

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Press Releases

March 8, 2022

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Press Releases

March 8, 2022

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Press Releases

March 8, 2022

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Press Releases

February 22, 2022

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Press Releases

February 22, 2022

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Press Releases

February 22, 2022

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Press Releases

February 22, 2022

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Press Releases

February 22, 2022

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Press Releases

February 22, 2022

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Press Releases

February 2, 2022

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Press Releases

February 2, 2022

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Press Releases

February 2, 2022

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Press Releases

February 2, 2022

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Press Releases

February 2, 2022

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Press Releases

February 2, 2022

Press Releases

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Acticor Biotech announces the issuance of a patent in Europe for glenzocimab, its innovative product for the treatment of cardiovascular emergencies

Acticor Biotech announces the issuance of a patent in Europe for glenzocimab, its innovative product for the treatment of cardiovascular emergencies

Acticor Biotech announces the issuance of a patent in Europe for glenzocimab, its innovative product for the treatment of cardiovascular emergencies

Acticor Biotech announces the issuance of a patent in Europe for glenzocimab, its innovative product for the treatment of cardiovascular emergencies

Acticor Biotech announces the issuance of a patent in Europe for glenzocimab, its innovative product for the treatment of cardiovascular emergencies

Acticor Biotech announces the issuance of a patent in Europe for glenzocimab, its innovative product for the treatment of cardiovascular emergencies

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

2021 full year financial results and update on clinical development

2021 full year financial results and update on clinical development

2021 full year financial results and update on clinical development

2021 full year financial results and update on clinical development

2021 full year financial results and update on clinical development

2021 full year financial results and update on clinical development

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Subscribe to email alert

Navigation

Contact Us